SGTX

Sigilon Therapeutics, Inc. Common Stock
SGTX

Overview Fund Activity
Delisted

SGTX was delisted on the 10th of August, 2023.

Back to rankings

48 hedge funds and large institutions have $26.8M invested in Sigilon Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
-2
Holders Change %
-4%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
21
Closed
7
Calls
$44K
Puts
$2K
Net Calls
+$42K
Net Calls Change
+$6K

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$405K
2
State Street
2
State Street
Massachusetts
$486K
3
Geode Capital Management
3
Geode Capital Management
Massachusetts
$363K
4
Cambridge Investment Research Advisors
4
Cambridge Investment Research Advisors
Iowa
$16K
5
Deutsche Bank
5
Deutsche Bank
Germany
$25K

Top Sellers

1
Morgan Stanley
1
Morgan Stanley
New York
$82K
2
Jacobs Levy Equity Management
2
Jacobs Levy Equity Management
New Jersey
$0
3
Vanguard Group
3
Vanguard Group
Pennsylvania
$456K
4
Millennium Management
4
Millennium Management
New York
$0
5
Nomura Holdings
5
Nomura Holdings
Japan
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Citadel Advisors
51
Citadel Advisors
Florida
– -$30K -838 Closed
Marshall Wace
52
Marshall Wace
United Kingdom
– -$10K -290 Closed
1 2
3